Deutsche Märkte geschlossen

AstraZeneca PLC (AZN.L)

LSE - LSE Verzögerter Preis. Währung in GBp
Zur Watchlist hinzufügen
7.930,00+35,00 (+0,44%)
Börsenschluss: 4:35PM BST

AstraZeneca PLC

1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
44 20 3749 5000
http://www.astrazeneca.com

Sektor(en)Healthcare
BrancheDrug Manufacturers—General
Vollzeitmitarbeiter76.100

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Mr. Pascal Soriot D.V.M., M.B.A.CEO & Exec. Director4,39MN/A1959
Mr. Marc DunoyerCFO & Exec. Director2,45MN/A1952
Ms. Pam P. ChengExec. Vice-Pres of Operations & Information TechnologyN/AN/A1971
Thomas Kudsk LarsenHead of Investor RelationsN/AN/AN/A
Mr. Jefrey PottExec. VP of HR & Gen. CounselN/AN/AN/A
Ms. Katarina AgeborgExec. VP of Sustainability & Chief Compliance OfficerN/AN/AN/A
Dr. Menelas PangalosExec. Vice-Pres of BioPharmaceuticals R&DN/AN/AN/A
Dr. Ruud DobberExec. Vice-Pres of BioPharmaceuticals Bus. UnitN/AN/AN/A
Dr. Susan Mary Galbraith M.D., Ph.D.Sr. VP and Head of Research, Early Devel. & Oncology R&DN/AN/A1966
Dr. David B. Goldstein Ph.D.Chief AdviserN/AN/AN/A
Die Beträge haben den Stand 31. Dezember 2020 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in GBp.

Beschreibung

AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; and Alchemab to enhance prostate cancer research. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Corporate Governance

AstraZeneca PLCs ISS Governance QualityScore, Stand 30. April 2021, lautet 5. Die grundlegenden Scores sind Audit: 1, Vorstand: 7, Shareholderrechte: 1, Kompensation: 4.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.